The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

Brenner, who has worked in the FDA’s Center for Devices and Radiological Health, will lead the agency until a permanent ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...